WO2017011982A1 - 贻贝粘蛋白产品及其抑制皮肤炎症的应用 - Google Patents
贻贝粘蛋白产品及其抑制皮肤炎症的应用 Download PDFInfo
- Publication number
- WO2017011982A1 WO2017011982A1 PCT/CN2015/084492 CN2015084492W WO2017011982A1 WO 2017011982 A1 WO2017011982 A1 WO 2017011982A1 CN 2015084492 W CN2015084492 W CN 2015084492W WO 2017011982 A1 WO2017011982 A1 WO 2017011982A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mussel mucin
- skin
- mussel
- mucin
- patients
- Prior art date
Links
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 114
- 108010004563 mussel adhesive protein Proteins 0.000 title abstract description 5
- 239000003988 mussel adhesive protein Substances 0.000 title abstract description 5
- 230000001629 suppression Effects 0.000 title abstract description 3
- 206010000496 acne Diseases 0.000 claims abstract description 22
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 21
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 21
- 231100000241 scar Toxicity 0.000 claims abstract description 21
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 18
- 206010040943 Skin Ulcer Diseases 0.000 claims abstract description 18
- 208000002847 Surgical Wound Diseases 0.000 claims abstract description 17
- 201000004384 Alopecia Diseases 0.000 claims abstract description 14
- 208000019872 Drug Eruptions Diseases 0.000 claims abstract description 14
- 208000000453 Skin Neoplasms Diseases 0.000 claims abstract description 13
- 208000024780 Urticaria Diseases 0.000 claims abstract description 13
- 230000001575 pathological effect Effects 0.000 claims abstract description 13
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims abstract description 12
- 231100000360 alopecia Toxicity 0.000 claims abstract description 12
- 238000001959 radiotherapy Methods 0.000 claims abstract description 12
- 231100000019 skin ulcer Toxicity 0.000 claims abstract description 12
- 206010016936 Folliculitis Diseases 0.000 claims abstract description 11
- 206010033072 otitis externa Diseases 0.000 claims abstract description 11
- 230000037380 skin damage Effects 0.000 claims abstract description 11
- 206010042496 Sunburn Diseases 0.000 claims abstract description 10
- 238000005299 abrasion Methods 0.000 claims abstract description 9
- 241000237536 Mytilus edulis Species 0.000 claims description 293
- 235000020638 mussel Nutrition 0.000 claims description 290
- 239000000047 product Substances 0.000 claims description 72
- 239000007788 liquid Substances 0.000 claims description 66
- 206010015150 Erythema Diseases 0.000 claims description 50
- 239000000499 gel Substances 0.000 claims description 50
- 231100000321 erythema Toxicity 0.000 claims description 35
- 239000002537 cosmetic Substances 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 21
- 230000036541 health Effects 0.000 claims description 20
- 208000010201 Exanthema Diseases 0.000 claims description 19
- 201000005884 exanthem Diseases 0.000 claims description 19
- 239000004088 foaming agent Substances 0.000 claims description 19
- 206010037844 rash Diseases 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 16
- 230000000249 desinfective effect Effects 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 235000013305 food Nutrition 0.000 claims description 12
- 201000000849 skin cancer Diseases 0.000 claims description 12
- 208000001034 Frostbite Diseases 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 239000011159 matrix material Substances 0.000 claims description 10
- 241000220317 Rosa Species 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 9
- 108010010803 Gelatin Proteins 0.000 claims description 7
- 239000008273 gelatin Substances 0.000 claims description 7
- 229920000159 gelatin Polymers 0.000 claims description 7
- 235000019322 gelatine Nutrition 0.000 claims description 7
- 235000011852 gelatine desserts Nutrition 0.000 claims description 7
- -1 Sodium dialkyl sulfate Chemical class 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- ZSAZGCBSZUURAX-UHFFFAOYSA-N 1-chloro-4-(diethoxyphosphorylsulfanylmethylsulfanyl)benzene Chemical compound CCOP(=O)(OCC)SCSC1=CC=C(Cl)C=C1 ZSAZGCBSZUURAX-UHFFFAOYSA-N 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- 108060003393 Granulin Proteins 0.000 claims description 4
- 101000574396 Homo sapiens Protein phosphatase 1K, mitochondrial Proteins 0.000 claims description 4
- 102100025799 Protein phosphatase 1K, mitochondrial Human genes 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- 230000003779 hair growth Effects 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 3
- RZXLPPRPEOUENN-UHFFFAOYSA-N Chlorfenson Chemical compound C1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=C(Cl)C=C1 RZXLPPRPEOUENN-UHFFFAOYSA-N 0.000 claims description 3
- 108010068370 Glutens Proteins 0.000 claims description 3
- 240000008042 Zea mays Species 0.000 claims description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 3
- 235000005822 corn Nutrition 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 235000021312 gluten Nutrition 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 229940051841 polyoxyethylene ether Drugs 0.000 claims description 3
- 229920000056 polyoxyethylene ether Polymers 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 210000004209 hair Anatomy 0.000 abstract description 16
- 201000004700 rosacea Diseases 0.000 abstract description 10
- 241001303601 Rosacea Species 0.000 abstract description 9
- 208000032544 Cicatrix Diseases 0.000 abstract description 8
- 230000037387 scars Effects 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 7
- 208000035874 Excoriation Diseases 0.000 abstract description 4
- 206010015218 Erythema multiforme Diseases 0.000 abstract 1
- 206010036087 Polymorphic light eruption Diseases 0.000 abstract 1
- 238000005516 engineering process Methods 0.000 abstract 1
- 102000015728 Mucins Human genes 0.000 description 261
- 108010063954 Mucins Proteins 0.000 description 261
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 42
- 210000003491 skin Anatomy 0.000 description 42
- 239000000243 solution Substances 0.000 description 41
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 31
- 208000003251 Pruritus Diseases 0.000 description 23
- 230000036407 pain Effects 0.000 description 23
- 230000007803 itching Effects 0.000 description 22
- 206010061218 Inflammation Diseases 0.000 description 15
- 206010033733 Papule Diseases 0.000 description 15
- 208000027418 Wounds and injury Diseases 0.000 description 15
- 239000000017 hydrogel Substances 0.000 description 15
- 230000004054 inflammatory process Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 235000011187 glycerol Nutrition 0.000 description 14
- 206010052428 Wound Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 239000011148 porous material Substances 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 230000006378 damage Effects 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 238000004659 sterilization and disinfection Methods 0.000 description 12
- 230000001154 acute effect Effects 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 11
- 238000005507 spraying Methods 0.000 description 11
- 230000000007 visual effect Effects 0.000 description 11
- 210000003780 hair follicle Anatomy 0.000 description 10
- 238000011084 recovery Methods 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 230000035876 healing Effects 0.000 description 9
- 230000003902 lesion Effects 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 239000002504 physiological saline solution Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 208000007514 Herpes zoster Diseases 0.000 description 8
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 230000002035 prolonged effect Effects 0.000 description 8
- 208000008742 seborrheic dermatitis Diseases 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000008034 disappearance Effects 0.000 description 7
- 210000000613 ear canal Anatomy 0.000 description 7
- 239000008176 lyophilized powder Substances 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 206010006802 Burns second degree Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 6
- 230000036592 analgesia Effects 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 229940014259 gelatin Drugs 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 231100000397 ulcer Toxicity 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 5
- 206010040844 Skin exfoliation Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000004761 scalp Anatomy 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 238000004088 simulation Methods 0.000 description 5
- 229920002907 Guar gum Polymers 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 4
- 206010049002 Scar pain Diseases 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 235000010417 guar gum Nutrition 0.000 description 4
- 239000000665 guar gum Substances 0.000 description 4
- 229960002154 guar gum Drugs 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000003273 male-pattern hair loss Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 210000001732 sebaceous gland Anatomy 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000000645 desinfectant Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 231100000444 skin lesion Toxicity 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 241000143233 Mytilus coruscus Species 0.000 description 2
- 241001245601 Perna viridis Species 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 241000669298 Pseudaulacaspis pentagona Species 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 206010041303 Solar dermatitis Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229960000292 pectin Drugs 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 230000036561 sun exposure Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010048961 Localised oedema Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- 241000237525 Mytilidae Species 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010052568 Urticaria chronic Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 208000003373 basosquamous carcinoma Diseases 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002219 extraembryonic membrane Anatomy 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 229940075469 tissue adhesives Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000004906 toe nail Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Abstract
Description
平均起效时间(min) | 3.3±1.2 |
使用前VAS平均评分 | 7.6±0.9 |
使用后VAS平均评分 | 1.4±0.3 |
平均止痒持续时间(h) | 8.2±2.1 |
平均痊愈时间(天) | 3.9±1.0 |
平均起效时间(min) | 3.8±2.1 |
使用前VAS平均评分 | 7.7±0.5 |
使用后VAS平均评分 | 1.3±0.2 |
平均止痒持续时间(h) | 6.9±2.1 |
平均痊愈时间(天) | 3.2±1.0 |
平均起效时间(min) | 12.6±3.7 |
使用前VAS平均评分 | 4.9±0.8 |
使用后VAS平均评分 | 1.1±0.4 |
平均止痒持续时间(h) | 5.6±1.7 |
平均痊愈时间(天) | 4.0±0.6 |
平均起效时间(min) | 10.2±2.6 |
使用前VAS平均评分 | 5.2±1.6 |
使用后VAS平均评分 | 1.0±0.7 |
平均止痒持续时间(h) | 6.6±1.3 |
平均痊愈时间(天) | 3.5±0.7 |
平均起效时间(min) | 6.2±1.8 |
使用前VAS平均评分 | 5.9±1.3 |
使用后VAS平均评分 | 1.0±0.6 |
平均止痒持续时间(h) | 13.6±1.3 |
平均痊愈时间(天) | 7.9±1.4 |
试验组 | 对照组 | |
平均起效时间(min) | 15.6±3.7 | 无缓解 |
使用前VAS平均评分 | 8.2±1.8 | 8.0±1.5 |
使用后VAS平均评分 | 2.4±0.5 | 8.0±0.6 |
平均止痛持续时间(h) | 8.6±1.1 | 无 |
平均愈合时间(天) | 3.9±0.4 | 6.2±0.7 |
试验组 | 对照组 | |
平均起效时间(min) | 14.0±2.9 | 无缓解 |
使用前VAS平均评分 | 8.1±1.6 | 8.0±1.2 |
使用后VAS平均评分 | 2.6±0.8 | 7.8±0.4 |
平均止痛持续时间(h) | 8.9±1.6 | 无 |
平均愈合时间(天) | 3.5±0.4 | 6.0±0.8 |
使用前VAS平均评分 | 8.1±1.5 |
使用后VAS平均评分 | 2.4±0.6 |
平均痊愈时间(天) | 17.9±2.4 |
使用前VAS平均评分 | 8.6±1.9 |
使用后VAS平均评分 | 2.3±0.8 |
平均痊愈时间(天) | 13.5±2.7 |
使用前VAS平均评分 | 7.0±0.5 |
使用后VAS平均评分 | 2.4±0.7 |
平均痊愈时间(天) | 16.4±3.1 |
使用前VAS平均评分 | 7.1±0.6 |
使用后VAS平均评分 | 2.3±0.9 |
平均痊愈时间(天) | 15.6±2.7 |
使用前VAS平均评分 | 7.0±0.5 |
使用后VAS平均评分 | 2.4±0.7 |
平均痊愈时间(天) | 16.4±3.1 |
Claims (16)
- 贻贝粘蛋白在治疗皮肤炎症中的应用。
- 根据权利要求1的贻贝粘蛋白应用,其中所述贻贝粘蛋白是来自亚类:mefp1、mefp-2、mefp-3、mefp-4、mefp-5、mefp-6、胶原蛋白pre-COL-P、pre-COL-D、pre-COL-NG、足丝基质蛋白PTMP和DTMP中的一种或几种的混合物。
- 根据权利要求1的贻贝粘蛋白应用,其中所述贻贝粘蛋白浓度为0.1-15.0mg/ml。
- 根据权利要求1的贻贝粘蛋白应用,其中所述贻贝粘蛋白是以液体剂、凝胶剂、凝露、糊剂、敷贴或泡沫剂使用。
- 根据权利要求1的贻贝粘蛋白应用,其中最终产品中的贻贝粘蛋白是在pH 1.0-7.0的范围内,特别是在pH 3.0-6.5的范围内。
- 根据权利要求1-5中任一项的贻贝粘蛋白应用,其中所述皮肤炎症选自:皮炎、湿疹、皮肤溃疡、烧伤术(含植皮)、冻疮、手术切口、疱疹、擦伤、疤痕、银屑病、多型红斑、放疗后皮肤损伤、皮肤癌、毛囊炎、荨麻疹、药疹。
- 根据权利要求1-5中任一项的贻贝粘蛋白应用,其中所述皮肤炎症选自:晒伤、多型性日光疹、病理性脱发(含植发)、寻常痤疮、玫瑰痤疮。
- 根据权利要求1-5中任一项的贻贝粘蛋白应用,其中所述皮肤炎症是外耳道炎。
- 贻贝粘蛋白作为活性成分在用于治疗皮肤炎症的组合物中的应用,其中所述组合物是以液体剂、凝胶剂、凝露、糊剂、敷贴或泡沫剂使用。
- 根据权利要求9的贻贝粘蛋白应用,其中所述组合物是皮肤外用。
- 贻贝粘蛋白作为活性成分在用于治疗皮肤炎症的药品中的应用。
- 贻贝粘蛋白作为活性成分在用于治疗皮肤炎症的化妆品中的应用。
- 贻贝粘蛋白作为活性成分在用于治疗皮肤炎症的消毒产品中的应用。
- 贻贝粘蛋白作为活性成分在用于治疗皮肤炎症的保健品或食品中的应用。
- 贻贝粘蛋白作为活性成分在用于治疗皮肤炎症的日化产品中的应用。
- 一种用于治疗皮肤炎症的泡沫剂,包括贻贝粘蛋白作为主要活性成分以及发泡剂基质材料,所述发泡剂基质材料选自羟丙甲基纤维素、明胶、聚乙二醇十二烷基硫酸钠、脂肪醇聚氧乙烯醚磺酸钠、玉米麸质粉、丙烯酰胺之一或其任意组合。
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/742,960 US10568938B2 (en) | 2015-07-20 | 2015-07-20 | Mussel adhesive protein product and applications thereof in suppression of skin inflammations |
JP2017568242A JP6778219B2 (ja) | 2015-07-20 | 2015-07-20 | 皮膚の炎症を抑制するイガイ接着タンパク質製品及びその適用 |
CN201580081675.6A CN108348577B (zh) | 2015-07-20 | 2015-07-20 | 贻贝粘蛋白产品及其抑制皮肤炎症的应用 |
DK15898538.2T DK3326639T3 (en) | 2015-07-20 | 2015-07-20 | Mussel adhesive protein product and applications thereof in suppression of skin inflammations |
CA2992109A CA2992109C (en) | 2015-07-20 | 2015-07-20 | Map product and use thereof for inhibiting skin inflammation |
KR1020187001311A KR102468519B1 (ko) | 2015-07-20 | 2015-07-20 | 피부 염증의 억제에서의 홍합 접착 단백질 제품 및 이의 적용 |
SG11201800440SA SG11201800440SA (en) | 2015-07-20 | 2015-07-20 | Mussel adhesive protein product and applications thereof in suppression of skin inflammations |
PCT/CN2015/084492 WO2017011982A1 (zh) | 2015-07-20 | 2015-07-20 | 贻贝粘蛋白产品及其抑制皮肤炎症的应用 |
AU2015402832A AU2015402832B2 (en) | 2015-07-20 | 2015-07-20 | Mussel adhesive protein product and applications thereof in suppression of skin inflammations |
CN202210132153.6A CN114558110A (zh) | 2015-07-20 | 2015-07-20 | 贻贝粘蛋白产品及其抑制皮肤炎症的应用 |
EP15898538.2A EP3326639B1 (en) | 2015-07-20 | 2015-07-20 | Mussel adhesive protein product and applications thereof in suppression of skin inflammations |
BR112018000953-9A BR112018000953A2 (zh) | 2015-07-20 | 2015-07-20 | Application of Mussel Mucin Products and Their Inhibition of Skin Inflammation |
MX2018000333A MX2018000333A (es) | 2015-07-20 | 2015-07-20 | Producto de la proteina adhesiva de mejillon y las aplicaciones de este en la supresion de inflamaciones de la piel. |
HK18114981.2A HK1255897A1 (zh) | 2015-07-20 | 2018-11-22 | 貽貝粘蛋白產品及其抑制皮膚炎症的應用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2015/084492 WO2017011982A1 (zh) | 2015-07-20 | 2015-07-20 | 贻贝粘蛋白产品及其抑制皮肤炎症的应用 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/742,960 A-371-Of-International US10568938B2 (en) | 2015-07-20 | 2015-07-20 | Mussel adhesive protein product and applications thereof in suppression of skin inflammations |
US16/732,436 Continuation US11260111B2 (en) | 2015-07-20 | 2020-01-02 | Mussel adhesive protein product and applications thereof in suppression of skin inflammations |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017011982A1 true WO2017011982A1 (zh) | 2017-01-26 |
Family
ID=57833543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2015/084492 WO2017011982A1 (zh) | 2015-07-20 | 2015-07-20 | 贻贝粘蛋白产品及其抑制皮肤炎症的应用 |
Country Status (13)
Country | Link |
---|---|
US (1) | US10568938B2 (zh) |
EP (1) | EP3326639B1 (zh) |
JP (1) | JP6778219B2 (zh) |
KR (1) | KR102468519B1 (zh) |
CN (2) | CN108348577B (zh) |
AU (1) | AU2015402832B2 (zh) |
BR (1) | BR112018000953A2 (zh) |
CA (1) | CA2992109C (zh) |
DK (1) | DK3326639T3 (zh) |
HK (1) | HK1255897A1 (zh) |
MX (1) | MX2018000333A (zh) |
SG (1) | SG11201800440SA (zh) |
WO (1) | WO2017011982A1 (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019007355A1 (en) * | 2017-07-05 | 2019-01-10 | Jiangyin Usun Pharmaceutical Co., Ltd. | ANTI-INFLAMMATORY USE OF PEPTIDE |
WO2019011286A1 (en) * | 2017-07-14 | 2019-01-17 | Jiangyin Usun Pharmaceutical Co., Ltd. | ANTIVIRAL USE OF MEMBRANE ADHESIVE PROTEINS |
CN110522667A (zh) * | 2019-08-08 | 2019-12-03 | 王斌 | 一种由纤连蛋白附着的面膜及其生产工艺 |
WO2020052677A1 (en) * | 2018-09-14 | 2020-03-19 | Jiangyin Usun Pharmaceutical Co., Ltd. | New conjugates of montelukast and peptides |
WO2020143744A1 (en) * | 2019-01-10 | 2020-07-16 | Jiangyin Mucocare Pharmaceutical Co., Ltd. | New formulations containing leukotriene receptor antagonists |
JP2020527134A (ja) * | 2017-07-05 | 2020-09-03 | ジャンイン ムコケア ファーマシューティカル カンパニー,リミテッド | モンテルカストおよびイガイ接着タンパク質との組み合わせを含む局所製剤 |
CN112236440A (zh) * | 2018-05-28 | 2021-01-15 | 江阴贝瑞森制药有限公司 | 新的药物用途 |
WO2021047648A1 (en) * | 2019-09-14 | 2021-03-18 | Jiangyin Usun Pharmaceutical Co., Ltd. | New peptides |
WO2021110061A1 (en) * | 2019-12-02 | 2021-06-10 | Jiangyin Usun Pharmaceutical Co., Ltd. | Peptides and their use in the treatment of inflammation |
WO2021110064A1 (en) * | 2019-12-02 | 2021-06-10 | Jiangyin Usun Biochemical Technology Co., Ltd. | New multi-functional oligopeptides |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108135972B (zh) | 2015-07-20 | 2022-07-01 | 江阴市本特塞缪森生命科学研究院有限公司 | 贻贝粘蛋白产品治疗和预防黑色素相关疾病中的应用 |
WO2017011986A1 (zh) | 2015-07-20 | 2017-01-26 | 赵兵 | 一种空气过滤装置 |
WO2017028025A1 (zh) | 2015-08-14 | 2017-02-23 | 江阴市本特塞缪森生命科学研究院有限公司 | 贻贝粘蛋白产品及其抑制粘膜炎症的应用 |
CN109925501A (zh) * | 2019-04-26 | 2019-06-25 | 贝亲母婴用品(上海)有限公司 | 一种用于改善皮肤屏障的组合物 |
CN110384651B (zh) * | 2019-09-05 | 2022-06-10 | 广州市华侬化妆品股份有限公司 | 修复过敏性皮肤及治疗湿疹的精华液 |
CN112315840A (zh) * | 2020-11-20 | 2021-02-05 | 广州植境生物科技有限公司 | 一种贻贝粘蛋白头皮修护组合物、修护液及其制备方法 |
KR102596264B1 (ko) | 2020-11-30 | 2023-11-01 | 주식회사 바이오빛 | 기능성 펩티드가 결합된 생체적합 폴리펩티드를 포함하는 염증 질환의 억제용 조성물 |
CN113975228B (zh) * | 2021-10-18 | 2023-06-23 | 江西省肿瘤医院(江西省第二人民医院、江西省癌症中心) | 一种妇科抗菌凝胶及其应用 |
CN117398511B (zh) * | 2023-10-18 | 2024-04-12 | 珠海市雅莎医疗器械有限公司 | 激光、光子术后修复的贻贝粘蛋白修护敷料及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1112831A (zh) * | 1994-05-30 | 1995-12-06 | 乌力吉 | 含蜗牛提取液的长效多功能营养护肤水及其制法 |
CN104645320A (zh) * | 2015-01-28 | 2015-05-27 | 南京航空航天大学 | 一种创面修复用贻贝粘蛋白凝胶剂及其制备方法和应用 |
CN104645313A (zh) * | 2015-01-28 | 2015-05-27 | 南京航空航天大学 | 一种修复止痒贻贝粘蛋白凝胶剂及其制备方法 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5605938A (en) | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
RU2043109C1 (ru) * | 1992-03-17 | 1995-09-10 | Маина Александровна Бичурина | Способ ингибиции вируса гриппа серотипов а и в |
AUPN531195A0 (en) * | 1995-09-11 | 1995-10-05 | J.W. Broadbent Nominees Pty. Ltd. | Lipid extract having anti-inflamatory activity |
NZ314867A (en) | 1997-05-21 | 1999-04-29 | Mcfarlane Lab New Zealand Ltd | Glucosamine and mussel extract compositions for use as anti-inflammatories |
WO1999064580A1 (en) | 1998-06-10 | 1999-12-16 | Georgia Tech Research Corporation | Microneedle devices and methods of manufacture and use thereof |
US20020018787A1 (en) * | 1999-05-21 | 2002-02-14 | Roger V. Kendall | Methods and compositions for modulating immune response and for the treatment of inflammatory disease |
DE60038320D1 (de) | 1999-07-21 | 2008-04-24 | Bomac Research Ltd | Mittel zur bekämpfung von entzündungen und/oder degenerativen erkrankungen |
WO2001012146A1 (en) | 1999-08-16 | 2001-02-22 | Playtex Products, Inc. | Sunscreen lotion or spray composition |
US7074433B2 (en) * | 2001-03-30 | 2006-07-11 | Council Of Scientific And Industrial Research | Process for the cure and control of Diabetes mellitus using natural products from Perna viridis |
US6770302B2 (en) * | 2001-03-30 | 2004-08-03 | Department Of Biotechnology | Indian green mussel (Perna viridis) as a source of anti-HIV activity |
US6905710B2 (en) * | 2001-08-31 | 2005-06-14 | Council Of Scientific And Industrial Research | Pharmaceutical composition useful for inhibition of osteoclast formation and a process for the extraction of mussel hudrolysate from indian green mussel |
US20060275370A1 (en) | 2002-07-25 | 2006-12-07 | Yih-Lin Chung | Method and compositions for treatment of epithelial damage |
US7704518B2 (en) * | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
CA2553775A1 (en) | 2004-01-20 | 2005-08-11 | Richard F. Harty | Compositions and methods of treatment for inflammatory diseases |
NZ563125A (en) * | 2005-06-03 | 2009-11-27 | Mcfarlane Marketing Aust Pty L | Lipid extract of mussels and method for preparation thereof |
KR100852864B1 (ko) * | 2007-04-13 | 2008-08-18 | 보령메디앙스 주식회사 | 초록입 홍합(Perna Canaliculus.)추출물을 함유하는 화장료 조성물 |
CN101348520B (zh) | 2007-12-14 | 2011-10-12 | 顾铭 | 一种使用混合吸附色谱分离纯化贻贝粘蛋白的方法 |
CN101348518B (zh) | 2007-12-14 | 2011-09-28 | 顾铭 | 一种使用羧甲基离子交换色谱纯化贻贝粘蛋白的方法 |
CN101585874B (zh) | 2009-06-30 | 2012-08-22 | 江阴贝瑞森生化技术有限公司 | 一种使用盐析和透析分离纯化贻贝粘蛋白的方法 |
CN101953813A (zh) * | 2009-07-16 | 2011-01-26 | 陕西步长制药有限公司 | 黄藤素泡腾片及其制法和检测方法 |
JP2012526155A (ja) | 2009-08-25 | 2012-10-25 | ポステック アカデミー−インダストリー ファンデーション | イガイ接着蛋白質またはその変異体に陰イオン性高分子が含まれたコアセルベート |
KR101147847B1 (ko) | 2010-06-02 | 2012-05-24 | 건국대학교 산학협력단 | 패류 유래 기능성 펩티드의 분리 정제 방법 및 기능성 펩티드의 용도 |
CN101991840B (zh) | 2010-09-26 | 2012-09-05 | 浙江海洋学院 | 抗前列腺癌贻贝酶解提取物的制备方法及应用 |
KR101384746B1 (ko) | 2011-08-24 | 2014-04-14 | 포항공과대학교 산학협력단 | 홍합 접착 단백질을 이용한 다양한 기능성 생체분자의 표면 고정화 |
CN102302417B (zh) | 2011-09-13 | 2012-12-26 | 佛山市安安美容保健品有限公司 | 一种含有海洋生物活性物质的全效防晒乳液 |
WO2013143077A1 (zh) | 2012-03-28 | 2013-10-03 | 江阴贝瑞森生化技术有限公司 | 使用多模式色谱纯化贻贝粘蛋白的方法 |
WO2014186937A1 (zh) | 2013-05-20 | 2014-11-27 | Gao Min | 贻贝粘蛋白凝胶的制备方法、贻贝粘蛋白凝胶及其应用 |
CN103520766A (zh) | 2013-09-25 | 2014-01-22 | 高敏 | 贻贝粘蛋白液体产品、其制备方法及其应用 |
CN104323927A (zh) * | 2014-11-06 | 2015-02-04 | 济南星河康泰贸易有限公司 | 贻贝粘蛋白在制备皮肤美容化妆品上的应用 |
CN104857552B (zh) | 2015-05-18 | 2018-08-10 | 赵明 | 一种止血贴及其制备方法 |
CN108135972B (zh) | 2015-07-20 | 2022-07-01 | 江阴市本特塞缪森生命科学研究院有限公司 | 贻贝粘蛋白产品治疗和预防黑色素相关疾病中的应用 |
WO2017028025A1 (zh) | 2015-08-14 | 2017-02-23 | 江阴市本特塞缪森生命科学研究院有限公司 | 贻贝粘蛋白产品及其抑制粘膜炎症的应用 |
-
2015
- 2015-07-20 BR BR112018000953-9A patent/BR112018000953A2/zh not_active Application Discontinuation
- 2015-07-20 CN CN201580081675.6A patent/CN108348577B/zh active Active
- 2015-07-20 SG SG11201800440SA patent/SG11201800440SA/en unknown
- 2015-07-20 CN CN202210132153.6A patent/CN114558110A/zh active Pending
- 2015-07-20 AU AU2015402832A patent/AU2015402832B2/en active Active
- 2015-07-20 WO PCT/CN2015/084492 patent/WO2017011982A1/zh active Application Filing
- 2015-07-20 KR KR1020187001311A patent/KR102468519B1/ko active IP Right Grant
- 2015-07-20 DK DK15898538.2T patent/DK3326639T3/da active
- 2015-07-20 US US15/742,960 patent/US10568938B2/en active Active
- 2015-07-20 EP EP15898538.2A patent/EP3326639B1/en active Active
- 2015-07-20 MX MX2018000333A patent/MX2018000333A/es unknown
- 2015-07-20 CA CA2992109A patent/CA2992109C/en active Active
- 2015-07-20 JP JP2017568242A patent/JP6778219B2/ja active Active
-
2018
- 2018-11-22 HK HK18114981.2A patent/HK1255897A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1112831A (zh) * | 1994-05-30 | 1995-12-06 | 乌力吉 | 含蜗牛提取液的长效多功能营养护肤水及其制法 |
CN104645320A (zh) * | 2015-01-28 | 2015-05-27 | 南京航空航天大学 | 一种创面修复用贻贝粘蛋白凝胶剂及其制备方法和应用 |
CN104645313A (zh) * | 2015-01-28 | 2015-05-27 | 南京航空航天大学 | 一种修复止痒贻贝粘蛋白凝胶剂及其制备方法 |
Non-Patent Citations (2)
Title |
---|
GAO, MIN ET AL.: "A Review on Mussel Adhesive Proteins", JOURNAL OF ANHUI AGRICULTURAL SCIENCES, vol. 39, no. 32, 30 November 2011 (2011-11-30), pages 19860 - 19862, XP009504646 * |
ZHU, YAOYAO ET AL.: "The Research Progress on Mussel Adhesive Proteins", ADVANCES IN MARINE SCIENCE, vol. 32, no. 4, 31 October 2014 (2014-10-31), pages 560 - 570, XP009504654 * |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020527135A (ja) * | 2017-07-05 | 2020-09-03 | ジャンイン ユスン ファーマシューティカル カンパニー,リミテッド | ペプチドの抗炎症的使用 |
WO2019007355A1 (en) * | 2017-07-05 | 2019-01-10 | Jiangyin Usun Pharmaceutical Co., Ltd. | ANTI-INFLAMMATORY USE OF PEPTIDE |
CN110139662A (zh) * | 2017-07-05 | 2019-08-16 | 江阴贝瑞森制药有限公司 | 肽的抗炎用途 |
AU2018295944B2 (en) * | 2017-07-05 | 2023-12-14 | Jiangyin MucoCare Pharmaceutical Co,. Ltd | Topical formulations comprising montelukast and combinations with mussel adhesive proteins |
CN110139662B (zh) * | 2017-07-05 | 2022-03-18 | 江阴贝瑞森制药有限公司 | 肽的抗炎用途 |
JP7288404B2 (ja) | 2017-07-05 | 2023-06-07 | ジャンイン ムコケア ファーマシューティカル カンパニー,リミテッド | モンテルカストおよびイガイ接着タンパク質との組み合わせを含む局所製剤 |
US11059859B2 (en) | 2017-07-05 | 2021-07-13 | Jiangyin Usun Pharmaceutical Co., Ltd. | Anti-inflammatory use of peptide |
JP2020527134A (ja) * | 2017-07-05 | 2020-09-03 | ジャンイン ムコケア ファーマシューティカル カンパニー,リミテッド | モンテルカストおよびイガイ接着タンパク質との組み合わせを含む局所製剤 |
US11672792B2 (en) | 2017-07-05 | 2023-06-13 | Enlitisa (Shanghai) Pharmaceutical Co., Ltd | Topical formulations comprising montelukast and combinations with mussel adhesive proteins |
CN114533850A (zh) * | 2017-07-05 | 2022-05-27 | 江阴贝瑞森制药有限公司 | 肽的抗炎用途 |
JP7198785B2 (ja) | 2017-07-05 | 2023-01-04 | ジャンイン ユスン ファーマシューティカル カンパニー,リミテッド | ペプチドの抗炎症的使用 |
EP3648767A4 (en) * | 2017-07-05 | 2021-04-28 | Jiangyin Mucocare Pharmaceutical Co., Ltd | TOPICAL FORMULATIONS INCLUDING MONTELUKAST AND COMBINATIONS WITH MOLD ADHESION PROTEINS |
WO2019011286A1 (en) * | 2017-07-14 | 2019-01-17 | Jiangyin Usun Pharmaceutical Co., Ltd. | ANTIVIRAL USE OF MEMBRANE ADHESIVE PROTEINS |
EP3802562A4 (en) * | 2018-05-28 | 2022-06-01 | Jiangyin Usun Pharmaceutical Co., Ltd. | NEW USE OF A DRUG |
CN112236440A (zh) * | 2018-05-28 | 2021-01-15 | 江阴贝瑞森制药有限公司 | 新的药物用途 |
JP2021525242A (ja) * | 2018-05-28 | 2021-09-24 | ジャンイン ユスン ファーマシューティカル カンパニー,リミテッド | 新たな医薬品使用 |
CN111601618A (zh) * | 2018-09-14 | 2020-08-28 | 江阴贝瑞森制药有限公司 | 孟鲁司特与肽的新缀合物 |
WO2020052677A1 (en) * | 2018-09-14 | 2020-03-19 | Jiangyin Usun Pharmaceutical Co., Ltd. | New conjugates of montelukast and peptides |
US11680082B2 (en) | 2018-09-14 | 2023-06-20 | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. | Conjugates of montelukast and peptides |
WO2020143744A1 (en) * | 2019-01-10 | 2020-07-16 | Jiangyin Mucocare Pharmaceutical Co., Ltd. | New formulations containing leukotriene receptor antagonists |
CN110522667A (zh) * | 2019-08-08 | 2019-12-03 | 王斌 | 一种由纤连蛋白附着的面膜及其生产工艺 |
WO2021047648A1 (en) * | 2019-09-14 | 2021-03-18 | Jiangyin Usun Pharmaceutical Co., Ltd. | New peptides |
WO2021110064A1 (en) * | 2019-12-02 | 2021-06-10 | Jiangyin Usun Biochemical Technology Co., Ltd. | New multi-functional oligopeptides |
WO2021110061A1 (en) * | 2019-12-02 | 2021-06-10 | Jiangyin Usun Pharmaceutical Co., Ltd. | Peptides and their use in the treatment of inflammation |
Also Published As
Publication number | Publication date |
---|---|
CN114558110A (zh) | 2022-05-31 |
AU2015402832B2 (en) | 2022-06-02 |
KR102468519B1 (ko) | 2022-11-21 |
CN108348577B (zh) | 2022-03-01 |
DK3326639T3 (en) | 2024-01-08 |
US20180228873A1 (en) | 2018-08-16 |
EP3326639A4 (en) | 2019-03-27 |
CN108348577A (zh) | 2018-07-31 |
SG11201800440SA (en) | 2018-02-27 |
JP2018525348A (ja) | 2018-09-06 |
HK1255897A1 (zh) | 2019-08-30 |
US10568938B2 (en) | 2020-02-25 |
MX2018000333A (es) | 2018-05-22 |
JP6778219B2 (ja) | 2020-10-28 |
CA2992109C (en) | 2022-10-11 |
EP3326639B1 (en) | 2023-11-01 |
BR112018000953A2 (zh) | 2018-09-11 |
EP3326639A1 (en) | 2018-05-30 |
AU2015402832A1 (en) | 2018-01-25 |
KR20180029228A (ko) | 2018-03-20 |
CA2992109A1 (en) | 2017-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017011982A1 (zh) | 贻贝粘蛋白产品及其抑制皮肤炎症的应用 | |
CN108135972B (zh) | 贻贝粘蛋白产品治疗和预防黑色素相关疾病中的应用 | |
CN106344956A (zh) | 一种壳聚糖抑菌促愈合凝胶及其制备方法 | |
EA032439B1 (ru) | Композиции и способы для лечения поверхностных ран | |
JP6807922B2 (ja) | 止血、組織障壁、創傷治癒、および美容術のための生体適合性カルボキシメチルセルロースマトリックス(bcm) | |
AU2013316718B2 (en) | Improved wound healing compositions comprising microspheres | |
WO2017011983A1 (zh) | 贻贝粘蛋白用于皮肤和皮肤附属器官的防护 | |
CN105709273B (zh) | 一种含聚乙二醇的液体医用敷料 | |
US11696907B2 (en) | Wound healing composition | |
CN112933214A (zh) | 一种促进伤口愈合的组合物 | |
US11260111B2 (en) | Mussel adhesive protein product and applications thereof in suppression of skin inflammations | |
KR101820519B1 (ko) | 설글리코타이드의 피부 상처 치유 촉진 용도, 및 이를 포함하는 외용제 조성물 | |
KR101607229B1 (ko) | 말기름을 함유하는 상처 치료용 조성물 | |
WO2020032902A2 (en) | Aksolotl blastema for use in the treatment of wounds and burns | |
CN117045844A (zh) | 一种含多聚糖的敷料及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15898538 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017568242 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15742960 Country of ref document: US Ref document number: MX/A/2018/000333 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2992109 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20187001311 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11201800440S Country of ref document: SG |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2015402832 Country of ref document: AU Date of ref document: 20150720 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015898538 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112018000953 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112018000953 Country of ref document: BR Kind code of ref document: A2 Effective date: 20180117 |